<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347086</url>
  </required_header>
  <id_info>
    <org_study_id>1241.8</org_study_id>
    <nct_id>NCT01347086</nct_id>
  </id_info>
  <brief_title>Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400mg, 800mg, 1200mg) of BI 207127 NA in Healthy Male Asian Volunteers and Single Oral Dose (1200 mg) of BI 207127 NA in Healthy Male Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Group)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate safety, tolerability and pharmacokinetics in Asian and
      Caucasian healthy male volunteers administered BI 207127 NA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Drug Related Adverse Events</measure>
    <time_frame>From first administration of study drug (drug related AEs) until 14 days after end of trial visit, upto 17 days.</time_frame>
    <description>Number of subjects with investigator-defined drug-related adverse events (AEs). Tolerability assessment endpoint.
The investigator assessed the possible causal relationship between all AEs and the investigational drug, considering all relevant factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, and confounding factors such as concomitant medication, concomitant diseases, and relevant history.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events as Determined by Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</measure>
    <time_frame>From signing the informed consent (within 21 days before drug administration) until 14 days after end of trial visit, upto 38 days.</time_frame>
    <description>Clinical relevant abnormalities for vital signs, blood chemistry, haematology, urinanalysis and ECG. Tolerability assessment endpoint.
New abnormal findings or worsening of baseline conditions were reported as adverse events. Adverse events were assessed through the entire trial, from signing the informed consent (within 21 days before drug administration) onwards through the observational phase until the end-of-trial-examination (within 14 days after last trial procedure).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of Deleobuvir</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h (hours) after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma (Deleobuvir) over the time interval from 0 extrapolated to infinity (AUC0-∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Deleobuvir</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma (Deleobuvir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Deleobuvir</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (Deleobuvir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of BI 208333 (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma (BI 208333) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 400mg&quot;, &quot;Japanese 800mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of BI 208333 (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma (BI 208333) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of BI 208333 (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (BI 208333).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of CD 6168 (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma (CD 6168) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 1200mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CD 6168 (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma (CD 6168).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CD 6168 (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (CD 6168).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma (CD 6168 Acylglucuronide) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 400mg&quot;, &quot;Japanese 800mg&quot;, &quot;Japanese 1200mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma (CD 6168 Acylglucuronide). The descriptive statistics of the arm &quot;Chinese 400mg&quot; cannot be determined due to limitation of available data above the &quot;below limit of quantification (BLQ)&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</measure>
    <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (CD 6168 Acylglucuronide).
The descriptive statistics of the arm &quot;Chinese 400mg&quot; cannot be determined due to limitation of available data above the &quot;below limit of quantification (BLQ)&quot;.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 207127 NA (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of BI 207127 NA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo (low dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 NA (medium dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of BI 207127 NA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo (medium dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 NA (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of BI 207127 NA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo (high dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo (low dose)</intervention_name>
    <description>single dose of matching placebo</description>
    <arm_group_label>Matching placebo (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 NA (medium dose)</intervention_name>
    <description>Single does of BI 207127 NA</description>
    <arm_group_label>BI 207127 NA (medium dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 NA (low dose)</intervention_name>
    <description>single dose of BI 207127 NA</description>
    <arm_group_label>BI 207127 NA (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo (medium dose)</intervention_name>
    <description>Single dose of matching placebo</description>
    <arm_group_label>Matching placebo (medium dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 NA (high dose)</intervention_name>
    <description>Single dose of BI 207127 NA</description>
    <arm_group_label>BI 207127 NA (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo (high dose)</intervention_name>
    <description>Single dose of matching placebo</description>
    <arm_group_label>Matching placebo (high dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male volunteers

          2. Chinese ethnicity or Japanese ethnicity or Caucasian

          3. Body Mass Index (BMI) = 18.5 and BMI =25 kg/m2 for Japanese and Chinese, BMI =18.5 and
             BMI = 29.9 kg/m2 for Caucasians

        Exclusion criteria:

          1. Any finding of the medical examination (including Blood pressure(BP), Pulse rate (PR)
             and Electrocardiogram (ECG)) deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.8.8201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related info</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>January 21, 2016</results_first_submitted>
  <results_first_submitted_qc>March 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2016</results_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>60 subjects were included (27 Chinese, 25 Japanese, and 8 Caucasian subjects). 24 Japanese and 24 Chinese subjects were randomised to 1 of 3 (rising) dose groups and received single oral doses of either 400mg, 800mg, or 1200mg of BI 207127 NA or of the respective placebo. Caucasian subjects were randomised to 1200 mg BI 207127 NA or placebo.</recruitment_details>
      <pre_assignment_details>The decision to proceed to the next higher dose group was based upon the safety of the preceding dose group. Caucasian subjects were randomised to receive either placebo or 1200 mg BI 207127 NA; this dose group could be started independently from the results of dose escalation in the Asian subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Caucasian Subjects)</title>
          <description>Caucasian subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P2">
          <title>1200 mg Deleobuvir (Caucasian Subjects)</title>
          <description>Caucasian subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Japanese Subjects)</title>
          <description>Japanese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P4">
          <title>400 mg Deleobuvir (Japanese Subjects)</title>
          <description>Japanese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P5">
          <title>800 mg Deleobuvir (Japanese Subjects)</title>
          <description>Japanese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P6">
          <title>1200mg Deleobuvir (Japanese Subjects)</title>
          <description>Japanese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P7">
          <title>Placebo (Chinese Subjects)</title>
          <description>Chinese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P8">
          <title>400 mg Deleobuvir (Chinese Subjects)</title>
          <description>Chinese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P9">
          <title>800 mg Deleobuvir (Chinese Subjects)</title>
          <description>Chinese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="P10">
          <title>1200 mg Deleobuvir (Chinese Subjects)</title>
          <description>Chinese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7">2 participants were treated together with each dose level of Deleobuvir.
1 subject was not treated.</participants>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7">2 participants treated together with each dose level of Deleobuvir.
1 subject was not treated.</participants>
                <participants group_id="P8" count="7">One subject was not treated.</participants>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="7">One subject was not treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>failed screening visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The treated set (full analysis set according to ICH-E9): all subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>1200 mg Deleobuvir (Caucasian Subjects)</title>
          <description>Caucasian subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Caucasian Subjects)</title>
          <description>Caucasian subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B3">
          <title>400 mg Deleobuvir (Japanese Subjects)</title>
          <description>Japanese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B4">
          <title>800 mg Deleobuvir (Japanese Subjects)</title>
          <description>Japanese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B5">
          <title>1200mg Deleobuvir (Japanese Subjects)</title>
          <description>Japanese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B6">
          <title>Placebo (Japanese Subjects)</title>
          <description>Japanese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B7">
          <title>400 mg Deleobuvir (Chinese Subjects)</title>
          <description>Chinese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B8">
          <title>800 mg Deleobuvir (Chinese Subjects)</title>
          <description>Chinese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B9">
          <title>1200 mg Deleobuvir (Chinese Subjects)</title>
          <description>Chinese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B10">
          <title>Placebo (Chinese Subjects)</title>
          <description>Chinese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="7.0"/>
                    <measurement group_id="B2" value="31.0" spread="8.5"/>
                    <measurement group_id="B3" value="28.8" spread="7.0"/>
                    <measurement group_id="B4" value="28.2" spread="4.6"/>
                    <measurement group_id="B5" value="23.7" spread="3.6"/>
                    <measurement group_id="B6" value="29.2" spread="7.1"/>
                    <measurement group_id="B7" value="24.7" spread="2.1"/>
                    <measurement group_id="B8" value="26.0" spread="3.9"/>
                    <measurement group_id="B9" value="23.7" spread="2.3"/>
                    <measurement group_id="B10" value="23.0" spread="2.1"/>
                    <measurement group_id="B11" value="26.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Drug Related Adverse Events</title>
        <description>Number of subjects with investigator-defined drug-related adverse events (AEs). Tolerability assessment endpoint.
The investigator assessed the possible causal relationship between all AEs and the investigational drug, considering all relevant factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, and confounding factors such as concomitant medication, concomitant diseases, and relevant history.</description>
        <time_frame>From first administration of study drug (drug related AEs) until 14 days after end of trial visit, upto 17 days.</time_frame>
        <population>Treated set (full analysis set according to the International Conference on Harmonization (ICH) E9 guideline): all subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1200 mg Deleobuvir (Caucasian Subjects)</title>
            <description>Caucasian subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Caucasian Subjects)</title>
            <description>Caucasian subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>400 mg Deleobuvir (Japanese Subjects)</title>
            <description>Japanese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>800 mg Deleobuvir (Japanese Subjects)</title>
            <description>Japanese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>1200mg Deleobuvir (Japanese Subjects)</title>
            <description>Japanese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Japanese Subjects)</title>
            <description>Japanese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>400 mg Deleobuvir (Chinese Subjects)</title>
            <description>Chinese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O8">
            <title>800 mg Deleobuvir (Chinese Subjects)</title>
            <description>Chinese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O9">
            <title>1200 mg Deleobuvir (Chinese Subjects)</title>
            <description>Chinese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Chinese Subjects)</title>
            <description>Chinese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Drug Related Adverse Events</title>
          <description>Number of subjects with investigator-defined drug-related adverse events (AEs). Tolerability assessment endpoint.
The investigator assessed the possible causal relationship between all AEs and the investigational drug, considering all relevant factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, and confounding factors such as concomitant medication, concomitant diseases, and relevant history.</description>
          <population>Treated set (full analysis set according to the International Conference on Harmonization (ICH) E9 guideline): all subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events as Determined by Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
        <description>Clinical relevant abnormalities for vital signs, blood chemistry, haematology, urinanalysis and ECG. Tolerability assessment endpoint.
New abnormal findings or worsening of baseline conditions were reported as adverse events. Adverse events were assessed through the entire trial, from signing the informed consent (within 21 days before drug administration) onwards through the observational phase until the end-of-trial-examination (within 14 days after last trial procedure).</description>
        <time_frame>From signing the informed consent (within 21 days before drug administration) until 14 days after end of trial visit, upto 38 days.</time_frame>
        <population>The treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>1200 mg Deleobuvir (Caucasian Subjects)</title>
            <description>Caucasian subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Caucasian Subjects)</title>
            <description>Caucasian subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>400 mg Deleobuvir (Japanese Subjects)</title>
            <description>Japanese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>800 mg Deleobuvir (Japanese Subjects)</title>
            <description>Japanese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>1200mg Deleobuvir (Japanese Subjects)</title>
            <description>Japanese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Japanese Subjects)</title>
            <description>Japanese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>400 mg Deleobuvir (Chinese Subjects)</title>
            <description>Chinese subjects who received 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O8">
            <title>800 mg Deleobuvir (Chinese Subjects)</title>
            <description>Chinese subjects who received 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O9">
            <title>1200 mg Deleobuvir (Chinese Subjects)</title>
            <description>Chinese subjects who received 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Chinese Subjects)</title>
            <description>Chinese subjects who received matching placebo.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events as Determined by Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
          <description>Clinical relevant abnormalities for vital signs, blood chemistry, haematology, urinanalysis and ECG. Tolerability assessment endpoint.
New abnormal findings or worsening of baseline conditions were reported as adverse events. Adverse events were assessed through the entire trial, from signing the informed consent (within 21 days before drug administration) onwards through the observational phase until the end-of-trial-examination (within 14 days after last trial procedure).</description>
          <population>The treated set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ of Deleobuvir</title>
        <description>Area under the concentration-time curve of the analyte in plasma (Deleobuvir) over the time interval from 0 extrapolated to infinity (AUC0-∞).</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h (hours) after drug administration</time_frame>
        <population>The pharmacokinetic (PK) analysis set: all evaluable subjects of the treated set who provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 400 mg</title>
            <description>Chinese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Deleobuvir</title>
          <description>Area under the concentration-time curve of the analyte in plasma (Deleobuvir) over the time interval from 0 extrapolated to infinity (AUC0-∞).</description>
          <population>The pharmacokinetic (PK) analysis set: all evaluable subjects of the treated set who provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
          <units>µmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" spread="45.5"/>
                    <measurement group_id="O2" value="14.0" spread="56.1"/>
                    <measurement group_id="O3" value="31.4" spread="52.3"/>
                    <measurement group_id="O4" value="48.2" spread="39.1"/>
                    <measurement group_id="O5" value="8.7" spread="78.7"/>
                    <measurement group_id="O6" value="42.6" spread="28.2"/>
                    <measurement group_id="O7" value="72.0" spread="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Deleobuvir</title>
        <description>Time from dosing to the maximum measured concentration of the analyte in plasma (Deleobuvir).</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 400 mg</title>
            <description>Chinese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Deleobuvir</title>
          <description>Time from dosing to the maximum measured concentration of the analyte in plasma (Deleobuvir).</description>
          <population>The PK analysis set.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.51" lower_limit="4.00" upper_limit="6.02"/>
                    <measurement group_id="O3" value="5.50" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="4.50" lower_limit="2.50" upper_limit="5.00"/>
                    <measurement group_id="O6" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O7" value="5.50" lower_limit="4.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Deleobuvir</title>
        <description>Maximum measured concentration of the analyte in plasma (Deleobuvir).</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 400 mg</title>
            <description>Chinese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Deleobuvir</title>
          <description>Maximum measured concentration of the analyte in plasma (Deleobuvir).</description>
          <population>The PK analysis set.</population>
          <units>µmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="42.0"/>
                    <measurement group_id="O2" value="3.2" spread="63.9"/>
                    <measurement group_id="O3" value="6.41" spread="47.4"/>
                    <measurement group_id="O4" value="8.26" spread="37.7"/>
                    <measurement group_id="O5" value="2.32" spread="75.5"/>
                    <measurement group_id="O6" value="8.89" spread="24.1"/>
                    <measurement group_id="O7" value="12.9" spread="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ of BI 208333 (Metabolite of Deleobuvir)</title>
        <description>Area under the concentration-time curve of the analyte in plasma (BI 208333) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 400mg&quot;, &quot;Japanese 800mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of BI 208333 (Metabolite of Deleobuvir)</title>
          <description>Area under the concentration-time curve of the analyte in plasma (BI 208333) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 400mg&quot;, &quot;Japanese 800mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
          <population>The PK analysis set.</population>
          <units>µmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="54.6"/>
                    <measurement group_id="O2" value="10.1" spread="54.2"/>
                    <measurement group_id="O3" value="5.97" spread="23.9"/>
                    <measurement group_id="O4" value="9.01" spread="186.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of BI 208333 (Metabolite of Deleobuvir)</title>
        <description>Time from dosing to the maximum measured concentration of the analyte in plasma (BI 208333) .</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 400 mg</title>
            <description>Chinese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of BI 208333 (Metabolite of Deleobuvir)</title>
          <description>Time from dosing to the maximum measured concentration of the analyte in plasma (BI 208333) .</description>
          <population>The PK analysis set.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="6.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="6.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="6.00" lower_limit="5.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="5.01" lower_limit="3.97" upper_limit="6.00"/>
                    <measurement group_id="O6" value="6.00" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O7" value="6.00" lower_limit="4.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of BI 208333 (Metabolite of Deleobuvir)</title>
        <description>Maximum measured concentration of the analyte in plasma (BI 208333).</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 400 mg</title>
            <description>Chinese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of BI 208333 (Metabolite of Deleobuvir)</title>
          <description>Maximum measured concentration of the analyte in plasma (BI 208333).</description>
          <population>The PK analysis set.</population>
          <units>µmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="42.8"/>
                    <measurement group_id="O2" value="0.59" spread="43.6"/>
                    <measurement group_id="O3" value="0.92" spread="54.2"/>
                    <measurement group_id="O4" value="1.32" spread="55.0"/>
                    <measurement group_id="O5" value="0.58" spread="26.8"/>
                    <measurement group_id="O6" value="0.86" spread="38.9"/>
                    <measurement group_id="O7" value="1.19" spread="104.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ of CD 6168 (Metabolite of Deleobuvir)</title>
        <description>Area under the concentration-time curve of the analyte in plasma (CD 6168) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 1200mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of CD 6168 (Metabolite of Deleobuvir)</title>
          <description>Area under the concentration-time curve of the analyte in plasma (CD 6168) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 1200mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
          <population>The PK analysis set.</population>
          <units>µmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="125.0"/>
                    <measurement group_id="O2" value="4.48" spread="85.8"/>
                    <measurement group_id="O3" value="11.0" spread="55.3"/>
                    <measurement group_id="O4" value="12.0" spread="25.1"/>
                    <measurement group_id="O5" value="22.2" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of CD 6168 (Metabolite of Deleobuvir)</title>
        <description>Time from dosing to the maximum measured concentration of the analyte in plasma (CD 6168).</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 400 mg</title>
            <description>Chinese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of CD 6168 (Metabolite of Deleobuvir)</title>
          <description>Time from dosing to the maximum measured concentration of the analyte in plasma (CD 6168).</description>
          <population>The PK analysis set.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="7.00" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="6.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="9.98" lower_limit="5.07" upper_limit="10.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="5.02" upper_limit="8.00"/>
                    <measurement group_id="O6" value="5.50" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O7" value="7.00" lower_limit="5.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of CD 6168 (Metabolite of Deleobuvir)</title>
        <description>Maximum measured concentration of the analyte in plasma (CD 6168).</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 400 mg</title>
            <description>Chinese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O7">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of CD 6168 (Metabolite of Deleobuvir)</title>
          <description>Maximum measured concentration of the analyte in plasma (CD 6168).</description>
          <population>The PK analysis set.</population>
          <units>µmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="80.7"/>
                    <measurement group_id="O2" value="0.57" spread="43.6"/>
                    <measurement group_id="O3" value="1.39" spread="34.3"/>
                    <measurement group_id="O4" value="2.65" spread="32.2"/>
                    <measurement group_id="O5" value="0.35" spread="109.0"/>
                    <measurement group_id="O6" value="1.66" spread="18.2"/>
                    <measurement group_id="O7" value="2.50" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</title>
        <description>Area under the concentration-time curve of the analyte in plasma (CD 6168 Acylglucuronide) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 400mg&quot;, &quot;Japanese 800mg&quot;, &quot;Japanese 1200mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</title>
          <description>Area under the concentration-time curve of the analyte in plasma (CD 6168 Acylglucuronide) over the time interval from 0 extrapolated to infinity. The descriptive statistics of the arms &quot;Japanese 400mg&quot;, &quot;Japanese 800mg&quot;, &quot;Japanese 1200mg&quot; and &quot;Chinese 400mg&quot; cannot be determined. The reason was that there were too few data to derive a terminal elimination rate constant (slope) to calculate AUC0-∞.</description>
          <population>The PK analysis set.</population>
          <units>µmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="114"/>
                    <measurement group_id="O2" value="0.56" spread="17.5"/>
                    <measurement group_id="O3" value="1.01" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</title>
        <description>Time from dosing to the maximum measured concentration of the analyte in plasma (CD 6168 Acylglucuronide). The descriptive statistics of the arm &quot;Chinese 400mg&quot; cannot be determined due to limitation of available data above the &quot;below limit of quantification (BLQ)&quot;.</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</title>
          <description>Time from dosing to the maximum measured concentration of the analyte in plasma (CD 6168 Acylglucuronide). The descriptive statistics of the arm &quot;Chinese 400mg&quot; cannot be determined due to limitation of available data above the &quot;below limit of quantification (BLQ)&quot;.</description>
          <population>The PK analysis set.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.01" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="8.00" lower_limit="6.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="9.98" lower_limit="6.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="10.00" lower_limit="5.07" upper_limit="10.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="5.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="8.00" lower_limit="5.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</title>
        <description>Maximum measured concentration of the analyte in plasma (CD 6168 Acylglucuronide).
The descriptive statistics of the arm &quot;Chinese 400mg&quot; cannot be determined due to limitation of available data above the &quot;below limit of quantification (BLQ)&quot;.</description>
        <time_frame>-2:00, 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 1200 mg</title>
            <description>Caucasian subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Japanese 400 mg</title>
            <description>Japanese subjects who received a single dose of 400 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Japanese 800 mg</title>
            <description>Japanese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Japanese 1200 mg</title>
            <description>Japanese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O5">
            <title>Chinese 800 mg</title>
            <description>Chinese subjects who received a single dose of 800 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
          <group group_id="O6">
            <title>Chinese 1200 mg</title>
            <description>Chinese subjects who received a single dose of 1200 mg Deleobuvir.
Oral with 240 mL of water in fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of CD 6168 Acylglucuronide (Metabolite of Deleobuvir)</title>
          <description>Maximum measured concentration of the analyte in plasma (CD 6168 Acylglucuronide).
The descriptive statistics of the arm &quot;Chinese 400mg&quot; cannot be determined due to limitation of available data above the &quot;below limit of quantification (BLQ)&quot;.</description>
          <population>The PK analysis set.</population>
          <units>µmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="62.3"/>
                    <measurement group_id="O2" value="0.03" spread="38.0"/>
                    <measurement group_id="O3" value="0.08" spread="48.2"/>
                    <measurement group_id="O4" value="0.11" spread="128.0"/>
                    <measurement group_id="O5" value="0.05" spread="29.0"/>
                    <measurement group_id="O6" value="0.07" spread="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed through the entire trial, from signing the informed consent (within 21 days before drug administration) onwards through the observational phase until the end-of-trial-examination (within 14 days after last trial procedure).</time_frame>
      <desc>Subjects were asked to spontaneously report any AEs as well as the time of onset, duration, and intensity. In addition, specific questions were asked whenever required or useful to more precisely describe an AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>All (Caucasian, Japanese and Chinese) subjects that received matching placebo. Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="E2">
          <title>400 mg Deleobuvir</title>
          <description>All (Japanese and Chinese) subjects that received 400 mg Deleobuvir. Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="E3">
          <title>800 mg Deleobuvir</title>
          <description>All (Japanese and Chinese) subjects that received 800 mg Deleobuvir. Oral with 240 mL of water in fed condition.</description>
        </group>
        <group group_id="E4">
          <title>1200 mg Deleobuvir</title>
          <description>All (Caucasian, Japanese and Chinese) subjects that received 1200 mg Deleobuvir. Oral with 240 mL of water in fed condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

